Navigation Links
MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
Date:12/16/2008

WARREN, N.J. and PORTAGE, Ind., Dec. 16 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today that the Company has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical PLC ("Hikma") (LSE: HIK) (DIFX: HIK), a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products across the Middle East and North Africa, the United States and Europe.

Under terms of the agreement, Hikma has acquired an exclusive license to distribute in the Middle East three thin film pharmaceutical products based on MonoSol Rx's proprietary PharmFilm delivery technology. Hikma will be responsible for obtaining all registrations and approvals required to market the products throughout the region. MonoSol Rx, which will exclusively supply the thin film products to Hikma, is eligible to receive milestone payments and payments for the purchase of product supply.

A. Mark Schobel, president and CEO of MonoSol Rx, stated, "We are excited to enter an agreement with Hikma that extends the geographic foothold of our proprietary PharmFilm technology. As a leading pharmaceutical company serving the Middle Eastern markets, we are confident in Hikma's ability to secure regulatory approvals and effectively sell three important thin film product formulations throughout the territory. In addition to expanding our reach into new geographic territories, our partnership with Hikma further validates our proprietary PharmFilm technology, leadership in thin film drug development, and growing intellectual property portfolio."

Said Darwazah, Chief Executive Officer of Hikma Pharmaceuticals PLC, said, "Our collaboration with MonoSol Rx is an excellent opportunity for us to offer different
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
2. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
4. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
5. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
6. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
7. Voonami, Inc. Announces Three New Adaptive Data Centers
8. Sentinelle Medical Enters OEM Distribution Agreement with Toshiba
9. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
10. American Pain Society Accepting Applications for Clinical Centers of Excellence in Pain Management Awards
11. Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Auckland, NZ (PRWEB) , ... August 30, 2015 ... ... enterprise collaboration across platforms and devices, today announced it is a Silver Sponsor ... 1, 2015 at Sky City Convention Centre in Auckland, NZ. Throughout the event, ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... InHealth Media. Nutritional Products International and InHealth media is a global sales and ... , “We are extremely pleased to continue our business relationship with Mr. Reid Eckert, ...
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the ... of the 10 regionally accredited Maricopa Community Colleges , will be hosting a ... students pursuing employment information and opportunities. , The Expo has expanded to much more ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk ... angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) ...
Breaking Medicine News(10 mins):Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... issue of Technology & Innovation, Proceedings of the ... bright future and enormous need for stem cell therapeutics ... and deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... cell replacement" procedures to restructure damaged organs, tissues and ...
... ICU , Intensive care units are facing staffing ... A recent study, conducted by physicians from Beth Israel ... York, NY, studying 590 daytime admissions in two intensive ... address these staff shortages. In the study, no ...
... 8 to 18 consume an average of 13 hours of ... their white counterparts, according to a Northwestern University report, the ... by race and ethnicity. "In the past decade, the ... doubled for blacks and quadrupled for Hispanics," says Northwestern Professor ...
... researcher in the University of Cincinnati (UC) Department of ... from the Emergency Medicine Foundation to study the implementation ... (ED). The award will support the work of ... of Medicine. Ward has spent the past year focusing ...
... This release is available in French . Montreal, ... needs to be decriminalized, according to a new report published in ... and University of Windsor researchers, the study calls for sweeping changes ... "We must not only change our laws, we must also revamp ...
... Houston environmental engineer will test parts of Galveston Bay ... officials determine the best way to handle those pollutants., ... through a Texas Commission on Environmental Quality (TCEQ) grant ... last fall for similar research in the Houston Ship ...
Cached Medicine News:Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2Health News:Dangerous and under the radar 2Health News:Dangerous and under the radar 3Health News:University of Houston researcher receives grant to study water pollutants 2
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by AstraZeneca plc, quetiapine (under ... drug for the treatment of schizophrenia. Approved by ... listed in the Catalogue of Drugs for the ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SAN MARINO, Calif. , July 6 ... of targeted genetic medicine, received a notice of allowance ... leading tumor-targeted gene delivery platform. The issuance of this ... follows on the heels of two major patent issuances ...
... N.J. , July 6 Nephros, Inc. (OTC Bulletin ... for therapeutic applications, infection control, and water purification, today reported that ... a standard component of its MRO portable reverse osmosis water treatment ... , ...
Cached Medicine Technology:Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 2Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 2Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 4Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 5
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
Medicine Products: